397 related articles for article (PubMed ID: 22017969)
1. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
[TBL] [Abstract][Full Text] [Related]
2. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
3. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
4. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
[TBL] [Abstract][Full Text] [Related]
5. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
Wu CS; Shang CY; Lin HY; Gau SS
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
[No Abstract] [Full Text] [Related]
6. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
[TBL] [Abstract][Full Text] [Related]
7. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
8. Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial.
Taş Torun Y; Işik Taner Y; Güney E; İseri E
Appl Neuropsychol Child; 2022; 11(4):567-578. PubMed ID: 32757634
[TBL] [Abstract][Full Text] [Related]
9. Differential long-term medication impact on executive function and delay aversion in ADHD.
Rubio Morell B; Hernández Expósito S
Appl Neuropsychol Child; 2019; 8(2):140-157. PubMed ID: 29244542
[TBL] [Abstract][Full Text] [Related]
10. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
Biederman J; Mick E; Fried R; Wilner N; Spencer TJ; Faraone SV
Eur Neuropsychopharmacol; 2011 Jul; 21(7):508-15. PubMed ID: 21303732
[TBL] [Abstract][Full Text] [Related]
11. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
[TBL] [Abstract][Full Text] [Related]
12. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
13. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
[TBL] [Abstract][Full Text] [Related]
14. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
15. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Starr HL; Kemner J
J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Gau SS; Shen HY; Soong WT; Gau CS
J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
[TBL] [Abstract][Full Text] [Related]
19. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
20. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]